The voice of Utah’s life sciences community

Medical Devices

Pharmaceuticals

Diagnostics / Laboratory

Biotechnology

BioUtah is the common voice and flag bearer for Utah’s life sciences industry, comprised of medical devices, pharmaceuticals, diagnostics, laboratories, research facilities, and biotechnology of all types. BioUtah connects industry with government, academia, capital markets, media, and service providers. Together we form an ecosystem that fosters collaboration, promotes innovation, and delivers technology that saves lives.

Icons made by Freepik from www.flaticon.com is licensed by CC 3.0 BY

BIO Business Solutions

Savings achieved through this program on lab supplies, equipment, shipping and much more, often exceed the annual cost membership in BioUtah.

Bill Tracker

With the Utah legislature in session, follow the bills BioUtah is tracking that affect the life sciences industry.

Featured New Member

Definium Therapeutics is forging a new era of psychiatry by applying precision to psychedelic medicine.

Utah Life Sciences by the Numbers

Kem C. Gardner Report Findings Nov. 2023

Utah is #3 in the nation for life sciences growth.

Life sciences is a $21.6 billion industry in Utah.

Source: Pace, L. and Brandley, A. (2023), Economic Impacts of Utah’s Life Sciences and Health Care Innovation Industry: Utah’s Life Sciences and Health Care Innovation Industry Creates Substantial Economic Impacts Across the State, Kem C. Gardner Policy Institute, University of Utah.

BioUtah News

August 20, 2026

Rep. Celeste Maloy Tours BIOS, Neurotech Innovation

U.S. Representative Celeste Maloy (R-UT) on Aug. 19 toured the Biologic Input Output Systems (BIOS) lab, part of the University of Utah’s Craig H. Neilsen Rehabilitation Hospital, to observe research into prosthetics innovation. Led by University of Utah NeuroRobotics Lab Director and BIOS Chief Scientist Jacob “Jake” George, alongside BIOS Chief Development Officer Tim Miller, […]

August 20, 2026

U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam for Pediatric Patients with Tourette Syndrome

Ecopipam (EBS-101) is a first-in-class selective D1 (dopamine) receptor antagonist with Orphan Drug designation

August 20, 2026

Sera Prognostics Appoints Scott Gleason CFO

SALT LAKE CITY, Aug. 19, 2026 /PRNewswire/ — Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, announced today that Scott Gleason has been appointed Chief Financial Officer (CFO), effective August 31, 2026. Mr. Gleason brings more than 25 […]

August 20, 2026

Merit Medical Announces Global Operations Leadership Transition

Sheri Lewis has agreed to join Merit as Executive VP of Global Operations, effective August 31.

August 20, 2026

Utah Life Sciences Innovation Caucus Breakfast

Utah lawmakers on Aug, 19 attended a breakfast meeting of the Utah Life Sciences Innovation Caucus (ULSIC).

August 20, 2026

Curavit Expands Clinical Research Capabilities with Acquisition of Lindus Health CRO Assets, Accelerating Global Trial Execution for Life Science Sponsors

Combined operations deliver unified trial delivery, faster recruitment, and expanded evidence-generation capabilities.

August 13, 2026

Sethera Therapeutics’ Polymacrocyclic Peptide Platform Selected for CDMRP-Supported Mutant p53 Breast Cancer Program

The award supports innovative, high-impact research aimed at advancing the prevention, diagnosis, and treatment of breast cancer.